CD19xCD22 bivalent CAR-T
Adoptive T cell therapy has shown a dramatic tumor suppression for some cancer patients, proving its potential for successful biotherapy. However, it still has major limitations: low cytotoxicity and long manufacturing time. Since 2000, CAR-T therapy has emerged as a promising adoptive T cell therapy due to remarkable advances in antibody technology, T cell therapy, and virus-based gene therapy.
Current CD19-targeting CAR-T therapies are far from being satisfactory due to a higher rate of disease relapse due to frequent CD19 antigen loss. InnoBation Bio is in the process of developing dual-specific CAR-T cells targeting both CD19 and CD22, hoping to go above and beyond. This dual-targeting module capturing each antigen can cover more cancer cells and give benefits to more lymphoma patients.
